scholarly journals Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD

Hepatology ◽  
2017 ◽  
Vol 67 (2) ◽  
pp. 492-504 ◽  
Author(s):  
Haesuk Park ◽  
Chao Chen ◽  
Wei Wang ◽  
Linda Henry ◽  
Robert L. Cook ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Kidney Disease ◽  
Chronic Hepatitis C ◽  
Hcv Treatment ◽  
Chronic Hepatitis C Virus ◽  
Incidence Of Ckd

scholarly journals Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease

Medicine ◽  
2020 ◽  
Vol 99 (42) ◽  
pp. e21972
Author(s):  
Sherief Abd-Elsalam ◽  
Yousry Esam-Eldin Abo-Amer ◽  
Mohamed El-Abgeegy ◽  
Samah A. Elshweikh ◽  
Heba Fadl Elsergany ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Kidney Disease ◽  
Chronic Hepatitis C ◽  
Efficacy And Safety ◽  
Chronic Hepatitis C Virus

Response of Ns5a inhibitors resistant patients to Qurevo-Sovaldi-Ribavirin regimen as a retreatment strategy for chronic hepatitis c virus infection

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Ahmed A Moanes ◽  
Hesham H Radwan ◽  
Yasser O Abd El Rahman ◽  
Mostafa M Abd El Nabi
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Hcv Treatment ◽  
Number Of Patients ◽  
Chronic Hepatitis C Virus ◽  
Chronic Hcv

Abstract Background Hepatitis C Virus (HCV) infection is a major global health challenge; it is estimated that more than 80 million people are chronically infected worldwide, with 3–4 million new infections and 350 000 deaths occurring each year because of HCV-related complications. Aim of the work to determine the efficacy of Qurevo-Sovaldi-Ribavirin regimen as a retreatment strategy in NS5A inhibitors (Sofosbuvir & Daclatasvir) resistant patients infected with chronic hepatitis C virus. Patients and Methods An observational cross-sectional study was carried out on 20 chronic hepatitis C virus infected patients in The centre of HCV treatment at El Quabary specialized centers in Alexandria where large number of patients receiving their HCV treatment. Results all patients (20/20) achieved sustained virological response after 3 months of the last dose of treatment (SVR12). Conclusion the new retreatment strategy composed of the triple therapy Qurevo (Ombitasvir/Paritaprevir/Ritonavir)/Sofosbuvir/Ribavirin is effective in the treatment of chronic HCV infected patients previously treated with Sofosbuvir/Daclatasvir/Ribavirin for 12 weeks without achieving sustained virological response (Ns5a inhibitors resistant chronic HCV patients).

Sign in / Sign up

Export Citation Format

Share Document